Literature DB >> 26407784

The role of regulators, investigators, and patient participants in the rise of the placebo response in major depressive disorder.

Maurizio Fava1.   

Abstract

Entities:  

Year:  2015        PMID： 26407784      PMCID： PMC4592651          DOI： 10.1002/wps.20247

Source DB:  PubMed          Journal:  World Psychiatry        ISSN： 1723-8617            Impact factor:   49.548


× No keyword cloud information.
  11 in total

1.  What's next after 50 years of psychiatric drug development: an FDA perspective.

Authors:  Thomas P Laughren
Journal:  J Clin Psychiatry       Date:  2010-09       Impact factor: 4.384

Review 2.  Vilazodone: clinical basis for the US Food and Drug Administration's approval of a new antidepressant.

Authors:  Thomas P Laughren; Jogarao Gobburu; Robert J Temple; Ellis F Unger; Atul Bhattaram; Phillip V Dinh; Linda Fossom; H M James Hung; Violetta Klimek; Jee Eun Lee; Robert L Levin; Cheri Y Lindberg; Mitchell Mathis; Barry N Rosloff; Sue-Jane Wang; Yaning Wang; Peiling Yang; Bei Yu; Huixia Zhang; Li Zhang; Issam Zineh
Journal:  J Clin Psychiatry       Date:  2011-09       Impact factor: 4.384

3.  Massachusetts General Hospital SAFER criteria for clinical trials and research.

Authors:  Martin Desseilles; Janet Witte; Trina E Chang; Nadia Iovieno; Christina Dording; Heidi Ashih; Maren Nyer; Marlene P Freeman; Maurizio Fava; David Mischoulon
Journal:  Harv Rev Psychiatry       Date:  2013 Sep-Oct       Impact factor: 3.732

4.  Trial designs advance to overcome bitter pill of placebo effect.

Authors:  Monica Heger
Journal:  Nat Med       Date:  2013-11       Impact factor: 53.440

5.  Assuring that double-blind is blind.

Authors:  Roy H Perlis; Michael Ostacher; Maurizio Fava; Andrew A Nierenberg; Gary S Sachs; Jerrold F Rosenbaum
Journal:  Am J Psychiatry       Date:  2010-03       Impact factor: 18.112

6.  Relationship between probability of receiving placebo and probability of prematurely discontinuing treatment in double-blind, randomized clinical trials for MDD: a meta-analysis.

Authors:  Enrico Tedeschini; Maurizio Fava; Tracie M Goodness; George I Papakostas
Journal:  Eur Neuropsychopharmacol       Date:  2010-03-09       Impact factor: 4.600

Review 7.  Review of maintenance trials for major depressive disorder: a 25-year perspective from the US Food and Drug Administration.

Authors:  Silvana Borges; Yeh-Fong Chen; Thomas P Laughren; Robert Temple; Hiren D Patel; Paul A David; Mitchell Mathis; Ellis Unger; Peiling Yang; Ni A Khin
Journal:  J Clin Psychiatry       Date:  2014-03       Impact factor: 4.384

8.  Evaluation of performance of some enrichment designs dealing with high placebo response in psychiatric clinical trials.

Authors:  Yeh-Fong Chen; Yang Yang; H M James Hung; Sue-Jane Wang
Journal:  Contemp Clin Trials       Date:  2011-04-20       Impact factor: 2.226

9.  Exploratory analyses of efficacy data from major depressive disorder trials submitted to the US Food and Drug Administration in support of new drug applications.

Authors:  Ni A Khin; Yeh-Fong Chen; Yang Yang; Peiling Yang; Thomas P Laughren
Journal:  J Clin Psychiatry       Date:  2011-04       Impact factor: 4.384

10.  Antidepressants versus placebo in major depression: an overview.

Authors:  Arif Khan; Walter A Brown
Journal:  World Psychiatry       Date:  2015-10       Impact factor: 49.548
View more
  1 in total

1.  Placebo response mitigation with a participant-focused psychoeducational procedure: a randomized, single-blind, all placebo study in major depressive and psychotic disorders.

Authors:  Elan A Cohen; Howard H Hassman; Larry Ereshefsky; David P Walling; Vera M Grindell; Richard S E Keefe; Katarzyna Wyka; William P Horan
Journal:  Neuropsychopharmacology       Date:  2020-11-26       Impact factor: 7.853
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.